**Inhibiting Runx1 protects heart function after myocardial infarction**

Tamara P Martin*1, Eilidh A MacDonald**1, Ashley Bradley*1, Holly Watson1, Priyanka Saxena1, Eva A. Rog-Zielinska2, Simon Fisher1, Ali Ali Mohamed Elbassioni1,3, Ohood Almuzaini1, Catriona Booth1, Morna Campbell1, Pawel Herzyk4,5, Karen Blyth6,7, Colin Nixon7, Lorena Zentilin8, Colin Berry1, Thomas Braun9, Mauro Giacca8,10, Martin W McBride1, Stuart A Nicklin1, Ewan R Cameron11, Christopher M Loughrey1**

*TPM, EAM and AB contributed equally to this work and as joint first authors can change the order of authorship for the purposes of curriculum vitae.

1 British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular & Medical Sciences, University of Glasgow, UK.

2 Institute for Experimental Cardiovascular Medicine, University Heart Centre Freiburg / Bad Krozingen, Faculty of Medicine, Freiburg, Germany.

3 Department of Cardiothoracic Surgery, Suez Canal University

4 Institute of Molecular, Cell and Systems Biology, University of Glasgow, UK.

5 Glasgow Polyomics, University of Glasgow, Garscube Campus, UK

6 Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

7 Cancer Research UK Beatson Institute, Garscube Estate, Glasgow, UK.

8 Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.

9 Department of Cardiac Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.

10 School of Cardiovascular Medicine and Sciences, King’s College London British Heart Foundation Centre, London, UK.

11 School of Veterinary Medicine, University of Glasgow, Garscube Campus, UK.

Address for correspondence:

**Christopher M Loughrey BVMS PhD MRCVS FHEA
University of Glasgow**
Institute of Cardiovascular & Medical Sciences

BHF Glasgow Cardiovascular Research Centre

University Place

Glasgow, G12 8TA, UK

Direct Line: +44 (0) 141 330 2753

Email: christopher.loughrey@glasgow.ac.uk

**Keywords:** Runx1, cardiomyocytes, sarcoplasmic reticulum, calcium handling, myocardial infarction border zone, adverse cardiac remodelling.
ABSTRACT

Myocardial infarction is a major cause of death worldwide. Effective treatments are required that limit adverse cardiac remodelling and preserve cardiac contractility following myocardial infarction, with the aim of improving patient outcomes and preventing progression to heart failure. The perfused but hypocontractile myocardium bordering a newly created infarct is functionally distinct from the remote surviving myocardium; it is also a major determinant of adverse cardiac remodelling and whole heart contractility. Expression of the transcription factor RUNX1 is increased in the border zone at 1 day after myocardial infarction, suggesting potential for targeted therapeutic intervention. Here we demonstrate that RUNX1 drives reductions in cardiomyocyte contractility, sarcoplasmic reticulum-mediated calcium release, mitochondrial density, and the expression of genes important for oxidative phosphorylation.

Antagonising RUNX1 expression via short-hairpin RNA interference preserved cardiac contractile function following myocardial infarction when delivered either via direct adenoviral delivery into the border zone or via an adeno-associated virus vector administered intravenously. Equivalent effects were obtained with a small molecule inhibitor (Ro5-3335) that reduces RUNX1 function by blocking its interaction with the essential co-factor CBFβ. Both tamoxifen-inducible Runx1-deficient and Cbfβ-deficient cardiomyocyte-specific mouse models demonstrated that antagonising RUNX1 function preserves the expression of genes important for oxidative phosphorylation following myocardial infarction. Our results confirm the translational potential of RUNX1 as a novel therapeutic target in myocardial infarction, with wider opportunities for use across a range of cardiac diseases where RUNX1 drives adverse cardiac remodelling.
INTRODUCTION

Myocardial infarction (MI) due to acute coronary artery blockage leads to cardiomyocyte death and an injury response culminating in the generation of three regions within the left ventricle (LV). The infarct zone (IZ) predominantly comprises fibrillar collagens that maintain the integrity of the myocardium and prevent LV wall rupture. The remote zone (RZ), is located furthest away from the IZ but over time develops several cellular and extracellular matrix changes that impact LV function. The border zone (BZ) surrounds the IZ; myocardium in this region is viable and perfused but hypocontractile. Cellular changes within these three regions are fundamental to the process of adverse cardiac remodelling, which manifests clinically as LV wall thinning, dilation and reduced contractility as early as 1 day post-MI\(^{1-6}\). Together with neurohumoral activation, adverse cardiac remodelling post-MI can lead to the clinical syndrome of heart failure (HF) with reduced ejection fraction, which despite optimised medical and device therapy is associated with high mortality rates\(^7\).

Cellular changes that occur in the BZ during the first few days post-MI play a critical role in the progression of LV remodelling, contractility, and patient prognosis during the subsequent weeks and months\(^8-10, 6,11,12\). Many of these BZ changes are conserved between mice and humans and include abnormal sarcoplasmic reticulum (SR)-mediated calcium release\(^1,2,13-16\) and the downregulation of genes important for mitochondrial oxidative phosphorylation\(^17\). The identification of drivers that induce these early changes in the BZ are critical for the development of new therapeutic approaches to prevent progression of adverse cardiac remodelling and development of HF following MI.

\textit{RUNX1} encodes a DNA-binding \(\alpha\)-subunit that partners with a common \(\beta\) subunit (CBF\(\beta\)) to form a heterodimeric transcription factor that acts as both an activator and repressor of target genes in normal development and disease\(^18\). Although RUNX1 has been intensively studied in cancer and haematology, its role in the heart is only just emerging\(^19\). \textit{Runx1} expression is increased in cardiomyocytes located within the BZ and IZ region as early as 1 day post-MI and mediates impaired contractility\(^20-22\). Whether this increased RUNX1 expression in the BZ can be therapeutically targeted to preserve contractility following MI remains unknown.

In this study, we address this knowledge gap by: (i) determining that the spatially restricted increased expression of RUNX1 in the BZ drives impaired calcium handling, a decrease in
mitochondrial density, and reduced expression of genes important for oxidative phosphorylation in the BZ; and (ii) revealing that multiple therapeutic approaches can be used to inhibit Runx1 in the BZ and thereby protect myocardial contractility following MI.
RESULTS

Calcium handling in BZ and RZ cardiomyocytes at 1 day post-MI

SR-mediated calcium release leads to sarcomere shortening and contraction, which are key processes determining LV pump function. Differences in BZ and RZ cardiomyocyte SR-mediated calcium release in the first week post-MI contribute to regional heterogeneity of contractile function across the LV. This regional heterogeneity contributes to impaired global LV contractile function and poor patient prognosis. Runx1 expression in BZ cardiomyocytes is increased as early as day 1 following MI. Whether this change in Runx1 expression at this time point simply coincides with, or impacts on, SR-mediated calcium handling was unknown. Therefore, we compared SR calcium handling in BZ and RZ cardiomyocytes isolated from the hearts of C57BL/6J and tamoxifen-inducible cardiomyocyte-specific Runx1-deficient (Runx1Δ/Δ) mice (and in Cre negative Runx1fl/fl littermate controls) at 1-day post-MI (Fig.1a). These results were compared to cardiomyocytes isolated from C57BL/6J hearts before MI at equivalent regions to where the “BZ” and “RZ” would be expected post-MI. Cardiomyocytes were stimulated at 1.0 Hz to elicit SR-mediated calcium release into the cytosol (calium transients), the amplitude of which largely determines the force of contraction (Fig.1a).

By contrast to hearts without MI (Fig.1b and 1c), the calcium transient peak (systolic [Ca2+]i) following MI in BZ cardiomyocytes was 64% of the peak in RZ cardiomyocytes (P<0.05; Extended Table 1a-c; Fig. 1g and 1h). In Runx1Δ/Δ hearts, the calcium transient peak was preserved in BZ cardiomyocytes relative to RZ cardiomyocytes (P>0.05; Fig. 1l and 1m). There was no difference in the diastolic [Ca2+]i (calcium transient minimum) between BZ and RZ in all groups (P>0.05; Extended Fig.1). Unlike hearts without MI (Fig. 1b and 1d), the changes in systolic [Ca2+]i in BZ cardiomyocytes following MI resulted in a calcium transient amplitude which was 47% of that observed in RZ cardiomyocytes (P<0.05; Fig.1g and 1i). By contrast, the calcium transient amplitude in BZ cardiomyocytes of Runx1Δ/Δ hearts was preserved (P>0.05; Fig. 1l and 1n; Extended Table 1).

The SR calcium content is the predominant determinant of calcium transit amplitude. To determine the SR calcium content, a rapid bolus of caffeine (10 mmol/L) was applied at the end of the protocol (Fig.1a) to release all the calcium from the SR into the cytosol, permitting the quantification of the SR calcium content. In contrast to hearts without MI (Fig.1e), the caffeine-induced Ca2+ transient amplitude (SR calcium content) of BZ cardiomyocytes at 1 day post-MI was 71% of that observed in
RZ cardiomyocytes (P<0.05; Fig. 1j; Extended Table 1). The SR calcium content of Runx1Δ/Δ BZ cardiomyocytes 1 day post-MI was not significantly different to that from RZ cardiomyocytes of the same hearts (P>0.05; Fig. 1o).

A key determinant of the SR calcium content is uptake into the SR via the calcium ATPase pump SERCA25. We hypothesised that the lowered SR calcium content in BZ cardiomyocytes following MI might reflect decreased SERCA activity (KSERCA) or enhanced extrusion of calcium from the cell via the sodium-calcium exchanger. To determine KSERCA, we measured the rate constant of decay of the caffeine-induced calcium transient (which includes sarcolemmal efflux but not SR calcium uptake) and subtracted this value from that of the electrically stimulated calcium transient (which includes both SR calcium uptake and sarcolemmal efflux)26,27. In contrast to hearts without MI (Fig.1f), KSERCA of BZ cardiomyocytes following MI was 48% of RZ cardiomyocytes (P<0.05; Fig. 1k; Extended Table 1). However, SERCA activity was not different between Runx1Δ/Δ BZ and RZ cardiomyocytes 1 day following MI (P>0.05; Fig.1p). Extrusion of calcium from the cell via the sodium-calcium exchanger was assessed by the time constant of caffeine-induced calcium transient decay but was not different between the BZ and RZ cardiomyocytes of any group (Extended Table 1).

Separate experiments confirmed that the relative difference between BZ and RZ in all parameters measured in C57BL/6J mice at 1-day post-MI (Fig.1 g-k) were also observed in Runx1fl/fl mice at 1 day post-MI (i.e. the Cre-negative littermate controls for Runx1Δ/Δ mice; Extended Table 1).

These data demonstrate that marked differences in SR-mediated calcium release/uptake between BZ and RZ cardiomyocytes that are known to contribute to whole heart contractile dysfunction in the first week post-MI, are evident as early as 1-day post-MI in both the C57BL/6J and littermate controls and are Runx1-dependent.

**RNA-sequencing analyses of BZ and RZ myocardium in Runx1Δ/Δ mice.**

The BZ is a discrete and highly active region of the myocardium post-MI that undergoes a considerable number of transcriptional changes, some of which ultimately may drive adverse cardiac remodelling. The extent to which the observed increase of Runx1 within the BZ plays a role in these transcriptional changes was unknown. Therefore, we used RNAseq to compare the changes in gene expression in the BZ myocardium relative to the RZ in both Runx1Δ/Δ and Runx1fl/fl control mice at 1
day following MI. Using a false discovery rate (FDR) cut-off of ≤ 0.05, there were 7166 differentially expressed genes in the BZ relative to the RZ in Runx1\textsuperscript{fl/fl} control mice (Fig. 2a). By contrast, there were only 1748 differentially expressed genes in the BZ relative to the RZ in Runx1\textsuperscript{Δ/Δ} mice. There were 1618 differentially expressed genes that were common to both Runx1\textsuperscript{Δ/Δ} and Runx1\textsuperscript{fl/fl} control mice leaving 130 differentially expressed genes unique to Runx1\textsuperscript{Δ/Δ} mice (Fig. 2a and 2b).

Ingenuity pathway analysis (IPA) software was used to determine the enriched pathways and functions specific to the 5548 differentially expressed genes unique to Runx1\textsuperscript{fl/fl} mice, as compared to the 130 differentially expressed genes unique to the Runx1\textsuperscript{Δ/Δ} mice. Oxidative phosphorylation was the most highly significant changed pathway/function (Fig. 2c).

Further interrogation of these pathways using IPA analysis of the total number of differentially expressed genes (between the BZ and RZ) in Runx1\textsuperscript{fl/fl} and Runx1\textsuperscript{Δ/Δ} post-MI, revealed marked downregulation of genes involved in oxidative phosphorylation across all five inner mitochondrial complexes in BZ myocardium of Runx1\textsuperscript{fl/fl} control mice (Fig. 3a and Extended Fig. 2). By contrast, no genes involved in oxidative phosphorylation within mitochondria were significantly downregulated in the BZ of Runx1\textsuperscript{Δ/Δ} mice suggesting that Runx1 deficiency within cardiomyocytes preserves genes involved in oxidative phosphorylation within the BZ following MI (Fig. 3b).

Mitochondria are critical for the energy production of the heart in the form of ATP generation via the process of oxidative phosphorylation. Given the marked preservation of expression of genes involved in oxidative phosphorylation within the BZ of Runx1\textsuperscript{Δ/Δ} mice, we next quantified mitochondrial density, integrity, and size from electron microscopy images taken from the BZ region of Runx1\textsuperscript{fl/fl} and Runx1\textsuperscript{Δ/Δ} mice at 1-day post-MI. The BZ of Runx1\textsuperscript{fl/fl} mice had reduced mitochondrial density compared to the BZ of Runx1\textsuperscript{Δ/Δ} mice (24% and 34% of cell area respectively, \(P<0.05\); Fig. 3c, 3d and 3h). There were significantly more damaged mitochondria (identified by dissolved/damaged cristae or mitophagosomes) in the BZ of Runx1\textsuperscript{fl/fl} mice (4.4% of all mitochondria) compared to the BZ of Runx1\textsuperscript{Δ/Δ} mice (1.5% of all mitochondria, \(P<0.05\); Fig. 3e-g and 3i). No difference in mitochondrial size was detectable between groups (Fig. 3j).
Targeted BZ knockdown of Runx1 by injection of adenoviral-Runx1-shRNA post-MI

We have previously shown that genetically modified cardiomyocyte-specific Runx1-deficient mice (Runx1Δ/Δ) have preserved left ventricle (LV) cardiac contractility following MI\(^20\). However, whether increased Runx1 expression post-MI in the BZ cardiomyocytes can be therapeutically targeted remained unknown. To address this gap in our knowledge we utilised various approaches. The first approach was to inject an adenoviral (Ad) vector expressing Runx1-shRNA (or control Ad-scrambled-shRNA) directly into the BZ area of C57BL/6J mice immediately following MI (Fig. 4a) to reduce Runx1 expression and determine the impact on LV contractility. The ability of the adenovirus to reduce Runx1 expression was first verified in IP1B cells, a murine cell line with high Runx1 expression (Extended Fig. 3). We next determined the efficiency of transduction and Runx1 expression (RNA hybridisation using RNAscope, as previously published\(^20\)) in cardiomyocytes (identified by PCM-1 expression) and other cardiac cells (Fig. 4b). There was no change in the total number of cardiomyocyte nuclei or non-cardiomyocyte nuclei between control and Ad-Runx1-shRNA groups within the IZ, BZ and RZ (Extended Fig. 4). Hearts injected with the control Ad-scrambled-shRNA demonstrated the expected increase in Runx1 expression within the IZ and BZ region of the LV; whereas Runx1 expression within the RZ of the LV remained low (Fig. 4c). Injection of Ad-Runx1-shRNA into the BZ resulted in a 46% reduction in Runx1 expression within cardiomyocyte nuclei relative to Ad-scramble-shRNA injected hearts (39.1±4.5 vs. 72.3±3.1% of total number of cardiomyocytes, \(P<0.05\); Fig. 4c). The reduction in Runx1 expression in cardiomyocytes was specific to the BZ region as there was no change in Runx1 expression within cardiomyocyte nuclei between the two groups in the other LV regions (Fig. 4c).

Echocardiography was performed before MI and at 1, 2 and 7 days post-MI to assess LV function (Fig. 4d). As expected, at 1 day post-MI there was a decline in cardiac systolic function (measured by fractional shortening; %FS) in the Ad-scramble-shRNA injected control group of mice which was maintained at a low level from day 1-7. By contrast, the Ad-Runx1-shRNA group had a markedly preserved contractile function at all time points post-MI relative to the Ad-scramble-shRNA injected control group (day 1, 34.7±1.8 vs. 26.4±1.9; day 2, 38.3±1.3 vs.; 26.4±1.7 and day 7, 40.9±0.9 vs. 28.5±0.6% FS; \(P<0.05\); Fig. 4e). The preservation of fractional shortening in C57BL/6J post-MI mice treated with Ad-Runx1-shRNA was attributable to an improved contractility as evidenced
by a smaller LV internal diameter (LVIDs) measured during systole at all time points post-MI relative to the Ad-scramble-shRNA injected control group (day 1, 2.4±0.1 vs. 3.0±0.1; day 2, 2.3±0.1 vs. 3.1±0.1 vs. day 7; 2.3±0.2 vs. 2.8±0.1mm LVIDs; P<0.05; Extended Table 2). The hearts of C57BL/6J mice treated with Ad-Runx1-shRNA were less dilated at 1 and 2 days post-MI as measured by the LV internal diameter measured during diastole (LVIDd) but was not different at 7 days post-MI between the groups (day 1, 3.7±0.1 vs. 4.1±0.2 [P<0.05]; day 2, 3.7±0.2 vs. 4.3±0.1 [P<0.05] day 7; 3.9±0.2 vs. 3.9±0.2mm [P>0.05]; Extended Table 2).

To determine whether a change in infarct size contributed to preserved cardiac function in C57BL/6J mice treated with Ad-Runx1-shRNA following MI, Sirius red staining was performed on heart slices (Fig. 4f). Infarct size was not different between the Ad-Runx1-shRNA and Ad-scramble-shRNA injected control group (P>0.05; Fig. 4f).

**Cardiac function and structure, and localised expression of Runx1 following treatment with AAV9-Runx1-shRNA post-MI**

Although knockdown of Runx1 in the BZ myocardium was effective in preserving cardiac contractile function, the need to directly inject the heart with the Ad may have reduced the translational potential of the approach. We, therefore, explored the use of a cardiotropic adeno-associated virus serotype 9 (AAV9) expressing a short-hairpin RNA targeting Runx1, which can be injected intravascularly to knockdown Runx1 within the heart. AAV vectors are widely used for cardiac gene delivery in pre-clinical models and clinical trials and a licensed AAV9 gene therapy is available for treatment of spinal muscular atrophy. AAV9 encoding shRNA provides highly efficient knockdown in the heart. AAV9-Runx1-shRNA or control AAV-scramble-shRNA were delivered via tail-vein injection following MI in C57BL/6J mice (Fig. 4g). Using RNAscope, we determined the expression of Runx1 within AAV9-Runx1-shRNA injected MI hearts relative to AAV9-scramble-shRNA within RZ, BZ and IZ of each heart at day 7 post-MI (Fig. 4h). Runx1 expression within cardiomyocyte nuclei of the BZ of mice injected with AAV9-Runx1-shRNA was 65% of the levels observed in mice injected with AAV9-scramble-shRNA (35.0±3.6 vs. 53.9±6.4% of total number of cardiomyocytes; P<0.05; Fig. 4i).

Despite a decrease in mean levels of Runx1 expression within cardiomyocyte nuclei in the RZ of mice injected with AAV9-Runx1-shRNA relative to mice injected with AAV9-scramble-shRNA, the observed
change was not significant (14.3±2.3 vs. 20.1±2.8; P>0.05; Fig. 4i). No significant change in Runx1 expression in cardiomyocytes was found in the IZ region (Fig. 4i). There was no change in the total number of cardiomyocyte nuclei or non-cardiomyocyte nuclei between control and AAV-Runx1-shRNA groups within the three regions assessed (Extended Fig. 4).

Echocardiography was performed before MI (day 0) and at 1 day and 7 days following MI to assess LV function (Fig. 4j). As expected, at 1 day post-MI there was a decline in cardiac systolic function (measured by fractional shortening; %FS) in the AAV9-scramble-shRNA injected control group which was maintained at a low level from days 1-7. By contrast, the AAV9-Runx1-shRNA group had a markedly preserved contractile function at day 1 and day 7 post-MI relative to the AAV9-scramble-shRNA injected control group (day-1, 37.7±1.4 vs. 27.6±1.4; day 7; 37.2±1.2 vs. 28.2±1.5% FS; P<0.05, Fig. 4k). The preservation of fractional shortening in C57BL/6J-MI mice treated with AAV9-Runx1-shRNA was attributable to an improved contraction as evidenced by a smaller LVIDs measured during systole at day 1 and day 7 post-MI relative to the AAV9-scramble-shRNA injected control group (day-1, 2.4±0.1 vs. 2.9 ±0.2; day 7, 2.5±0.1 vs. 3.1±0.2mm; P<0.05; Extended Table 2). Cardiac dilation was not significantly affected by AAV9-Runx1-shRNA as LV internal diameter measured during diastole was not different at day 1 and day 7 post-MI (Extended Table 2).

In contrast to direct injection of AdRunx1-shRNA into the BZ, intravenous injection of AAV9-Runx1-shRNA reduced infarct size in C57BL/6J-MI mice relative to AAV9-scramble-shRNA group post-MI (41.4±1.9 vs. 31.1±3.5% of LV; P<0.05; Fig. 4l).

**Small molecule mediated inhibition of Runx1 post-MI**

RUNX1 partners with CBFβ to act as a heterodimeric transcription factor\(^{18}\). Interfering with RUNX1 binding to CBFβ significantly reduces affinity for RUNX1 binding to its target genes thus its transcriptional activity. The benzodiazepine derivative Ro5-3335 is an established RUNX1 inhibitor that alters the interaction between RUNX1 and CBFβ\(^{31}\). We used Ro5-3335 in two different protocols as an alternative therapeutic approach to gene transfer in the context of MI (Fig. 5a). The first protocol involved pre-treatment with Ro5-335 in C57BL/6J mice every other day for 7 days followed by the same treatment pattern following MI. Echocardiography was performed before MI (day 0) and at 1, 3,
and 7 days following MI to assess LV function (Fig. 5b). At 1 day post-MI there was a decline in cardiac systolic function (measured by %FS) in the vehicle-injected group of mice that was maintained at a low level from day 1 to 7. By contrast, the Ro5-3335 injected group had a preserved contractile function at days 1 and 7 points post-MI relative to the vehicle control group (day 1, 37.6±2.2 vs. 30.1±0.6; day 3, 40.4±3.5 vs. 32.8±1.2; day 7; 38.8±2.0 vs. 30.1±2.2% FS; \(P<0.05\), Fig. 5b).

The second protocol involved post-treatment with Ro5-3335 in C57BL/6J mice every day for 7 days following MI. Echocardiography was performed before MI (day 0) and at 1, 3, and 7 days following MI to assess LV function (Fig. 5a; Extended Table 2). At 1 day post-MI there was a decline in cardiac systolic function (measured by %FS) in the vehicle injected group of mice that was maintained at a low level from day 1 to day 7 (Fig. 5c). By contrast, the Ro5-3335 injected group had a markedly preserved contractile function at all time points post-MI relative to the vehicle control group (day 1, 32.2±1.8 vs. 26.2±1.5; day 3, 38.6±3.2 vs. 24.6±2.4; day 7; 33.3±0.6 vs. 26.6±1.9% FS; \(P<0.05\), Fig. 5c).

As observed in previous studies that have used Ro5-3335 to inhibit Runx1 in other tissues\(^{32}\), Runx1 expression in LV myocardium was decreased relative to vehicle control (\(P<0.05\); Fig. 5d).

These data confirm that both gene therapeutic and pharmacological approaches to inhibit Runx1 preserve cardiac contractile function following MI.

**Generation of a cardiomyocyte-specific Cbfβ deficient mouse to inhibit RUNX1 function**

We next sought to confirm our results with Ro5-3335 using an organ-specific approach to limit the potential for CBFβ to interact with RUNX1. This was achieved by generating a tamoxifen-inducible cardiomyocyte-specific CBFβ deficient mouse using the Cre-LoxP system. \(Cbf\beta^{fl}\) mice, described previously\(^{33}\), were crossed with mice expressing tamoxifen-inducible Cre recombinase (MerCreMer) under the control of the cardiac-specific \(\alpha\)MHC (\(\alpha\)-myosin heavy chain)\(^{34}\) to produce the relevant test \(Cbf\beta^{\Delta\Delta}\) and littermate control \(Cbf\beta^{fl}\) cohorts (Fig. 5e). Expression of Cbfβ was reduced to 77% and 47% in LV myocardium and isolated cardiomyocytes respectively in \(Cbf\beta^{\Delta\Delta}\) mice relative to control \(Cbf\beta^{fl}\) mice (Fig. 5f and 5g).
Echocardiography was performed the day before MI (day 0) and at 1 and 7 days following MI to assess LV function in CbfβΔ/Δ mice relative to control Cbfβfl/fl mice (Fig. 5h). As expected, at 1 day post-MI there was a decline in cardiac systolic function (measured by %FS) in Cbfβfl/fl mice which was maintained at a low level from day 1 to 7. By contrast, CbfβΔ/Δ mice demonstrated a preserved contractile function at day 7 post-MI relative to control Cbfβfl/fl mice (35.2±2.2 vs. 25.3±1.5% FS; P<0.05, Fig. 5h).

These data support the findings with Ro5-3335 that limiting RUNX1 function by reducing availability of its essential co-factor CBFβ in cardiomyocytes preserves cardiac function.

RNA-sequencing analyses of LV myocardium in CbfβΔ/Δ and Cbfβfl/fl mice.

We next determined whether there was any similarity between the pathways altered in CbfβΔ/Δ mice to our findings with Runx1Δ/Δ mice (Fig. 2) using an unbiased RNAseq approach. LV myocardium taken before MI (day 0) and 7 days after MI was compared in both CbfβΔ/Δ and Cbfβfl/fl control mice. Using a FDR of 0.05, there were 7860 differentially expressed genes in Cbfβfl/fl control mice when comparing the day 0 and day 7 time points (Figure 6a). By contrast, there were only 2995 differentially expressed genes in CbfβΔ/Δ mice (Fig. 6a). There were 2747 differentially expressed genes that were common to both CbfβΔ/Δ and Cbfβfl/fl control mice leaving 5113 differentially expressed genes unique to Cbfβfl/fl mice and not significantly affected in CbfβΔ/Δ (Fig. 6a and 6b). These overall numbers are very similar to those shown in Runx1Δ/Δ mice (Fig. 2). IPA software was used to determine the enriched pathways and functions specific to the 5113 differentially expressed genes unique to Cbfβfl/fl mice compared to the 248 differentially expressed genes unique to the CbfβΔ/Δ mice. As with our finding with Runx1Δ/Δ mice, oxidative phosphorylation was the most significantly changed pathway (Fig. 6c).

Further interrogation of the pathway revealed marked downregulation of 87% of genes involved in oxidative phosphorylation across all five inner mitochondrial complexes in Cbfβfl/fl mice (Fig. 6d). By contrast, only 47% of mitochondrial genes were downregulated in the CbfβΔ/Δ mice demonstrating that cardiomyocyte deficiency in CBFβ or Runx1 preserves mitochondrial gene expression following MI (Fig. 6e).
DISCUSSION

Our study reveals original and important insights into two key aspects of RUNX1 function. The first finding relates to the impact of the spatially restricted increase of Runx1 in BZ myocardium observed within the first day following MI. We demonstrate this phenomenon drives abnormal SR-mediated calcium handling, downregulation of mitochondrial gene expression, and a reduced number of mitochondria in the BZ relative to the RZ. Second, we demonstrate the therapeutic potential of inhibiting RUNX1 activity/expression using multiple translational approaches. These manipulations markedly and robustly preserve cardiac contractile function following MI. These discoveries have potential for clinical translation.

It is increasingly recognised that events that occur in the first few days post-MI play a critical role in the progression of LV remodelling during the following weeks and months. LV contractile function is substantially reduced as early as 1-day post-MI. Critically at this time point, across species, there is a regional heterogeneity of contractile function across the LV wall contributing to impaired global LV contractile function and poor patient prognosis. The most severe contractile dysfunction in the surviving myocardium is in the BZ region (where Runx1 expression is highest) and least dysfunction in the RZ region (where Runx1 expression is lowest). Calcium handling within cardiomyocytes is one of the key determinants of cardiac contractile function. Here, we demonstrate that abnormal calcium handling in BZ cardiomyocytes occurs as early as 1 day post-MI. The abnormalities include a reduced calcium transient amplitude, SR calcium content and SERCA activity in BZ cardiomyocytes relative to cardiomyocytes isolated from the RZ region. These data are supported by previous studies that demonstrate that the BZ region has reduced SERCA expression, calcium transient amplitude and contraction at 3-7 days following MI. In contrast, the amplitude of calcium release, SR calcium content and SERCA activity was not significantly different between the BZ and RZ region in Runx1-deficient mice post-MI demonstrating homogeneous calcium handling across regions that is likely to contribute to the improved LV contractile function observed in Runx1-deficient mice at 1 day following MI. Our previous results at the later time point of 2 weeks post-MI demonstrated a role for Runx1 in determining SERCA-mediated calcium uptake, SR calcium content and calcium transient amplitude. The current study provides new insight in that this function of Runx1 is evident in BZ cardiomyocytes as early as 1 day post-MI.
Our RNAseq study comparing the BZ and RZ in Runx1-deficient mice produced remarkable evidence for a new role for RUNX1 in reducing mitochondria function and number in the BZ following MI. Mitochondria are essential for the generation of vast amounts of energy required by the heart in the form of ATP. The mitochondria generates more than 95% of this ATP by oxidative phosphorylation. Myocardial infarction is commonly characterised by changes in energy/substrate metabolism and decreased mitochondrial function with abnormalities of ATP production being more severe in the BZ relative to the RZ. This pattern, which occurs across species (rodents, sheep, pigs, zebrafish, and humans), coincides with a parallel reduction in the expression of genes associated with oxidative phosphorylation, reduced BZ contractile function and progression to HF.

Our study provides new insight demonstrating that Runx1 in the BZ drives a reduction in the expression of genes associated with mitochondrial oxidative phosphorylation as early as 1 day post-MI and likely contributes to impaired BZ contractile function. Our electron microscopy revealed that as early as 1 day following MI both mitochondria number and architecture is reduced/impaired respectively in the BZ. By contrast, the BZ of our Runx1-deficient mice had preserved expression of genes associated with mitochondrial oxidative phosphorylation relative to the RZ, and displayed a higher number of structurally normal mitochondria relative to control hearts post-MI. Mitochondrial size (and therefore potentially changes to mitochondrial fusion/fission) were not altered by Runx1.

This new link between RUNX1 and mitochondrial function has profound implications for cardiac contractility and patient outcome and warrants future investigation. For example, the extent to which the expression of genes associated with oxidative phosphorylation in the BZ of Runx1-deficient mice post-MI is regulated by effects of RUNX1 on mitochondria number (via altered balance of mitochondrial destruction/biogenesis), a multitude of genes or a key regulator remains an intriguing area to explore.

Given the potential of Runx1 deficiency in cardiomyocyte-specific genetically modified mice to improve two key indices of BZ cardiomyocyte contractility (i.e., calcium handling and mitochondrial function) we tested whether targeting RUNX1 expression/activity in the BZ of wild type mice could enhance contractility post-MI. We first used two viral vector-mediated gene delivery approaches of Runx1-shRNA to knockdown Runx1 within the BZ. Both of these approaches resulted in a marked preservation of LV contractile function post-MI. The level of improved contractility was equivalent to
that observed in cardiomyocyte-specific Runx1 deficient mice. One unexpected difference between
the two approaches was that, in contrast to direct BZ myocardial injection of Ad-Runx1-shRNA,
intravenous injection of AAV9-Runx1-shRNA produced a small but statistically significant reduction of
infarct size following MI. It is unclear why this difference in infarct size was only present when using
AAV9-Runx1-shRNA but it is unlikely to explain the preservation of contractile function since direct
myocardial BZ injection of Ad-Runx1-shRNA produced the same level of preserved LV contractility
without a change in infarct size. This conclusion is also supported by our previous published work in
cardiomyocyte-specific Runx1 deficient mice where infarct size was not altered, yet cardiac
contractility was preserved post-MI.

Our next approach was to use Ro5-3335, a small molecule specific inhibitor of RUNX1. Cardiac
contractile function was preserved post-MI when Ro5-3335 was delivered either before or
immediately after MI (the latter being a potential translational approach). Ro5-3335 is able to directly
interact with RUNX1 and its cofactor CBFβ significantly reducing the transcriptional activity of
RUNX1. Ro5-3335 has previously been shown to improve pulmonary hypertension and retinal
angiogenesis by altering vascular remodelling, endothelial to haemopoietic transition and pulmonary
macrophage activity. Given the ability of Ro5-3335 to inhibit RUNX1-dependent processes outside
the heart it was important to determine that the preservation in contractile function observed in Ro5-
3335 treated mice was related to a direct effect on cardiomyocytes. To that end, we developed a
tamoxifen-inducible cardiomyocyte-specific Cbfβ deficient mouse to limit Runx1 activity in
cardiomyocytes in a similar way to Ro5-3335. CBFβ deficient mice also demonstrated preserved LV
contractile function thus confirming (alongside our four other approaches to inhibit RUNX1 within the
heart) that inhibiting RUNX1 within cardiomyocytes is a therapeutically tractable approach with
translational potential to preserve cardiac contractile function following MI. Similar to our findings in
Runx1-deficient mice, the Cbfβ-deficient mice had preserved expression levels of oxidative
phosphorylation genes following MI, thus highlighting a common RUNX1-dependent mechanism
observed in more than one of our approaches to inhibit RUNX1 activity in cardiomyocytes. Given that
RUNX1 is a master transcription factor that controls multiple cellular processes, we anticipate
potential for non-cardiomyocyte effects of small molecule based RUNX1 inhibition (e.g., vascular
remodelling) that may contribute also to improved LV function. Indeed, using Runx1 as a multi-

targeted approach to cardioprotection could be more beneficial than single-target based therapy to prevent adverse cardiac remodelling\textsuperscript{45}.

Although the current study focuses on RUNX1 in the context of MI our findings have broader implications for RUNX1 biology in other tissues and diseases (cardiac and non-cardiac)\textsuperscript{19}. Increased RUNX1 expression is now observed in hypertension-induced cardiac hypertrophy\textsuperscript{46}, diabetes-induced heart dysfunction\textsuperscript{47} and dilated cardiomyopathy\textsuperscript{22,48} all of which involve impaired energy production\textsuperscript{49,50}. The atria of patients with atrial fibrillation also demonstrate increased Runx1 expression\textsuperscript{51}. Whether expression of Runx1 alters propensity for arrhythmias warrants future investigation. With regards to non-cardiac diseases, increased RUNX1 expression is a key contributor to retinal vascular dysfunction\textsuperscript{44}, liver disease\textsuperscript{52}, septic shock\textsuperscript{53} and kidney dysfunction\textsuperscript{54}. In support of our work on the therapeutic potential of RUNX1 inhibitors in the setting of myocardial infarction, Ro5-3335 has been successfully used to improve both cardiac\textsuperscript{55} and non-cardiac related diseases\textsuperscript{56}. It is becoming increasingly clear that RUNX1 inhibitors may represent a future therapy for a wide range of diseases including MI. Furthermore, given the importance of our novel data linking increased RUNX1 expression to mitochondrial number and oxidative phosphorylation, this study opens up the potential to explore the importance of RUNX1 in cellular processes/diseases where mitochondrial oxidative phosphorylation gene expression is demonstrated to be decreased; for example, mitochondrial disorders\textsuperscript{57} and age-associated organ dysfunction\textsuperscript{58}.

In summary, the BZ myocardium is an important hypocontractile region of the heart post-MI the pathology of which influences progression to adverse cardiac remodelling and heart failure. We have demonstrated that RUNX1 drives pathological changes within BZ cardiomyocytes as early as 1 day post-MI; in particular a reduction in SR calcium release, mitochondrial number and expression of genes involved in oxidative phosphorylation necessary for ATP production. Inhibition of Runx1 by gene therapeutic approaches or the use of a small molecular inhibitor improves LV cardiac contractile function and represents a new translational approach with the potential to treat patients with MI and limit progression to heart failure.
ACKNOWLEDGMENTS

Funding was received from the British Heart Foundation (PG/18/933548 and RG/20/6/35095) to CML and MG (RG/19/11/34633) and the Wellcome Trust (204820/Z/16/Z) to TPM. EARZ is a German Research Foundation Emmy Noether Fellow (DFG #396913060) and a member of the German Research Foundation Collaborative Research Centre SFB1425 (DFG #422681845). Ali Elbassioni is funded by the Newton-Mosharafa Fund. CRUK core funding to the Beatson Institute (A31287) and to Karen Blyth (A29799). The authors thank Michael Dunne, Margaret Bell, and Catherine Hawksby at the University of Glasgow for their surgical, animal, and technical assistance; as well as Dr Martin Schorb and Dr Rachel Mellwig at EMBL Heidelberg Electron Microscopy Core Facility for access to and assistance with electron microscopy and tomography. We thank Douglas Strathdee, the Transgenic Technologies Lab, BSU and Histology lab at the Beatson Institute. We thank Vicky Heath for editorial assistance.
AUTHOR CONTRIBUTIONS

Tamara P Martin: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing- Original draft and Review and Editing, Supervision, Project administration; Eilidh A MacDonald: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing- Original draft and Review and Editing, Visualization, Supervision, Project administration; Ashley Bradley: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing- Review and Editing; Holly Watson: Methodology, Formal analysis, Investigation; Priyanka Saxena: Validation, Formal analysis, Investigation; Eva Rog-Zielinska: Methodology, Validation, Formal analysis, Investigation; Simon Fisher: Formal analysis; Catriona Booth: Formal analysis; Morna Campbell: Formal analysis; Ali Ali Mohamed Elbassioni: Formal analysis, Investigation; Ohood Almuzaini: Formal analysis, Investigation; Pawel Herzyk: Formal analysis; Karen Blyth: Writing- Review and Editing; Colin Nixon: Investigation, Resources; Lorena Zentilin: Resources; Colin Berry: Writing- Review and Editing; Thomas Braun: Conceptualization, Writing- Review and Editing; Mauro Giacca: Resources; Writing- Review and Editing; Martin McBride: Formal analysis, Investigation, Writing- Review and Editing, Supervision; Stuart A Nicklin: Supervision, Writing- Review and Editing, Funding acquisition; Ewan Cameron: Conceptualization, Supervision, Writing- Review and Editing, Funding acquisition; Christopher M Loughrey: Conceptualization, Formal analysis, Writing- Original draft and Review and Editing, Supervision, Project administration, Resources, Data Curation, Funding acquisition.
COMPETING INTERESTS STATEMENT

None
METHODS

Mice

The care and use of animals were in accordance with the UK Government Animals (Scientific Procedures) Act 1986. All animal procedures were approved by the University of Glasgow Animal Welfare and Ethical Review Body and licensed by the Home Office, UK (project licence no. P05FEIF82). Mice were housed on a 12/12 h light/dark cycle and fed and watered ad libitum. All animals used were male mice aged 10-12 weeks of age (weight, 25-30 g) and were randomly assigned to experimental groups.

Generation of cardiomyocyte-specific Runx1 and Cbfβ deficient mice

Runx1Δ/Δ mice were generated as previously described20. Cbfβfl/fl mice33 (The Jackson Laboratory, ME, USA) were crossed with mice expressing tamoxifen-inducible Cre recombinase (MerCreMer) under the control of the cardiac-specific αMHC (α-myosin heavy chain)34 to generate the relevant test (CbfβΔ/Δ) and littermate (Cbfβfl/fl) control groups.

Coronary artery ligation

Thoracotomy and left anterior descending coronary artery permanent ligation surgeries were performed on C57BL/6J (Envigo), Runx1-deficient, Cbfβ-deficient and respective floxed control mice using previously published standard approaches (see Extended Methods)59,60.

Calcium measurements

Cardiomyocytes from C57BL/6J and Runx1-deficient mice were isolated according to region (see Extended Methods). BZ and remote RZ were loaded with a calcium-sensitive fluorophore (5.0 μmol/L Fura-4F AM, Invitrogen), and perfused during field stimulation (1.0 Hz, 2.0ms duration, stimulation voltage set to 1.5 times the threshold). Data were analysed offline as previously described61.

RNA sequencing sample preparation and analysis

RNA was extracted using the miRNeasy Mini Kit (Qiagen, UK) from BZ and RZ myocardial tissue from control Runx1fl/fl and Runx1Δ/Δ mice pre-MI as well as 1 day post-MI and whole LV myocardial
tissue from Cbfβ<sup>fl/fl</sup> and Cbfβ<sup>Δ/Δ</sup> pre-MI and 7 days post-MI. Sequencing libraries were enriched using polyA tail selection and samples were run on a Next Seq500 Sequencing system (Illumina) at the Glasgow Polyomics research facility (see Extended Methods). Global functional, network, and canonical pathway analyses were performed using Ingenuity Pathways Analysis (IPA). Genes shown in the article text and figures were generated by IPA and therefore might exclude lncRNAs and pseudogenes that are not recognised by the IPA software.

**Electron Microscopy**

Hearts were perfused with cardioplegic solution, immediately followed by perfusion-fixation with iso-osmotic Karnovsky’s fixative (2.4% sodium cacodylate, 0.75% paraformaldehyde, 0.75% glutaraldehyde) and then separated into BZ and RZ. Thin (90 nm) and semi-thick (300 nm, for dual-axis electron tomography) sections were prepared and imaged at the Electron Microscopy Core Facility, European Molecular Biology Laboratory (EMBL) Heidelberg, using 300 kV Tecnai TF30 (FEI Company, now Thermo-Fisher Scientific, Eindhoven, The Netherlands). Tilt series were aligned, reconstructed, and combined using IMOD. Mitochondrial density, quantity, and damage was analysed using IMOD software and ImageJ (see Extended Methods).

**Adenoviral knockdown of Runx1 in the border zone region**

The Ad-Runx1-shRNA<sup>62</sup> and a random scramble sequence (Ad-scramble-shRNA) were purchased from Vector Biolabs (USA; Gene ID: 12394). Following coronary artery ligation, the BZ area was injected with 5 x 10<sup>μL</sup> of either Ad-scramble-shRNA or Ad-Runx1-shRNA (1 x 10<sup>9</sup> viral particles per heart) immediately following MI (see Extended Methods).

**AAV-mediated knockdown of Runx1**

Following coronary artery ligation, mice were intravenously injected via the tail vein with either AAV9-scramble-shRNA or AAV9-Runx1-shRNA (1x10<sup>11</sup> virus particles per mouse) in a randomised fashion immediately following MI (see Extended Methods).
Ro5-3335 knockdown of Runx1

C57BL/6J mice were randomly assigned to receive either vehicle (100% DMSO) or 20 mg/kg of Ro5-3335 (Tocris-Bioscience, UK) given subcutaneously. Mice assigned to protocol 1 received either Ro5-3335 or vehicle at 7, 5, 3 and 1 day before coronary artery ligation then again at 1, 3, 5 and 7 days following coronary artery ligation. Mice assigned to protocol 2 received Ro5-3335 or vehicle at the time of coronary artery ligation and on consecutive days until day 7.

Echocardiography

M-mode measurements were performed prior to left anterior descending coronary artery ligation and in the days following as previously published.

Histology

Quantification of regional areas and infarct size was performed on Picosirius Red-stained histological sections with ImageJ and Adobe Photoshop as previously described. RNAscope with probes to specifically identify cardiomyocyte nuclei (pericentriolar material 1; PCM1) and Runx1 was performed. For each heart, positive (Ppib and Polr2a) and negative controls (bacterial dapB) were run (Extended figure 4).

Statistics

Data were expressed as mean ± SEM. Comparisons between two experimental groups were performed with the Student’s t-test on raw data before normalization to percentage change where appropriate. Comparisons between more than two groups were conducted on raw data with ANOVA. In experiments where multiple isolated cardiomyocyte observations (n) were obtained from each heart, we first ensured normality of the data distribution and then determined the differences between control and experimental mice using mean data from each heart (and not individual cardiomyocytes; IBM SPSS Statistics, version 22).
REFERENCES


61. Elliott EB, Hasumi H, Otani N, Matsuda T, Matsuda R, Kaneko N, Smith GL and Loughrey CM. K201 (JTV-519) alters the spatiotemporal properties of diastolic Ca(2+) release and the
associated diastolic contraction during beta-adrenergic stimulation in rat ventricular cardiomyocytes.


Figure 1. Excitation-contraction coupling in C57BL/6J and Runx1Δ/Δ mice and 1 day post-myocardial infarction (MI). (a) Protocol. (b) Typical calcium (Ca²⁺) transients before MI in C57BL/6J mice in the “remote zone” (“RZ”) and “border zone” (“BZ”). (c) Mean Ca²⁺ transient peak, (d) mean Ca²⁺ transient amplitude n=76 (9 hearts) and from the BZ n=43 (9 hearts), (e) Mean caffeine-induced Ca²⁺ transient amplitude and (f) mean sarcoendoplasmic reticulum calcium transport ATPase (SERCA) activity from C57BL/6J mice from RZ, n=76 (8 hearts) and from the BZ n=43 (8 hearts). (g) Typical Ca²⁺ transients 1 day post-MI in C57BL/6J mice in the RZ and BZ. (h) Mean Ca²⁺ transient peak, (i) mean Ca²⁺ transient amplitude, (j) mean caffeine-induced Ca²⁺ transient amplitude and (k) mean SERCA activity from C57BL/6J 1-day post-MI mice from RZ, n=64 (7 hearts) and from the BZ n=30 (7 hearts). (l) Typical Ca²⁺ transients 1-day post-MI in Runx1Δ/Δ mice in the RZ and BZ. (m) Mean Ca²⁺ transient peak, (n) mean Ca²⁺ transient amplitude, (o) mean caffeine induced Ca²⁺ transient amplitude and (p) mean SERCA activity from Runx1Δ/Δ mice 1-day post-MI mice from RZ, n=16 (4 hearts) and from the BZ n=9 (4 hearts). Error bars represent mean ± SEM. **P<0.01, ***P<0.001.

Figure 2. RNA sequencing comparisons and analysis between border zone (BZ) and remote zone (RZ) in Runx1fl/fl and Runx1Δ/Δ mice 1 day post-myocardial infarction (MI). (a) Schematic of comparison and Venn diagram of gene differences. (b) Volcano plots of differentially regulated genes unique to Runx1fl/fl mice (left, black) and Runx1Δ/Δ mice (right, red) in the BZ versus the RZ at 1 day post-MI. Top five upregulated and down regulated genes based on false discovery rate (FDR) are noted. (c) Enriched biological pathways ranked by logP (B-H p value) using IPA analysis from unique differences in Runx1fl/fl mice (circles) compared with BZ and RZ differences in Runx1Δ/Δ mice (triangles). Blue-to-orange heatmap and symbol colours represent predicted inhibition (blue) and activation (orange) or no change (grey) of pathways based on Z-score.

Figure 3. Oxidative phosphorylation and mitochondrial density in the border zone (BZ) of Runx1fl/fl and Runx1Δ/Δ mice 1 day post-myocardial infarction (MI). Schematic visualisation of genes involved in oxidative phosphorylation complexes from the RNAseq data from the border zone (BZ) and remote zone (RZ) in Runx1fl/fl and Runx1Δ/Δ mice 1 day post-MI in
Ingenuity Pathway Analysis (IPA) (downregulated – green, upregulated – red, no difference – white) of (a) Runx1\textsubscript{fl/fl} mice (7166 differentially expression genes) and (b) Runx1\textsubscript{ΔΔ} mice (1748 differentially expressed genes). Low resolution electron microscopy images from BZ of (c) Runx1\textsubscript{fl/fl} mice and (d) Runx1\textsubscript{ΔΔ} mice. Mitochondria are outlined in yellow, with damaged mitochondria indicated by yellow arrows. High-resolution electron tomography representative images of (e-f) damaged mitochondria from the BZ of Runx1\textsubscript{fl/fl} mice 1 day post-MI and (g) healthy mitochondria from the BZ of Runx1\textsubscript{ΔΔ} mice 1 day post-MI. Quantification of (h) mitochondrial density as a percentage of cell area, (i) the number of damaged mitochondria as a percentage of the total number of mitochondria, and (j) average mitochondrial size from electron microscopy images of the BZ from Runx1\textsubscript{fl/fl} mice and Runx1\textsubscript{ΔΔ} mice 1 day post-MI n=92 (2 hearts). Error bars represent mean ± SEM. *P<0.05, unpaired Student t-test on average heart data.

Figure 4. Cardiac function and Runx1 expression in Ad-Runx1-shRNA and AAV-Runx1-shRNA mice. (a) Schematic representation of Ad given via an injection into the border zone immediately after induction of MI. (b-e) Typical images of regional heart sections by RNA in situ hybridisation (using RNAscope). Regions examined were the remote zone (RZ), infarct zone (IZ) and border zone (BZ) at 7 days post-MI in Ad-Runx1-shRNA injected mice (n=4) and Ad-scramble-shRNA injected mice (n=4). Probes for Runx1 (pink punctate dots) and pericentriolar material 1 (PCM-1) (brown punctate dots) were used. Scale bar, 10 µm; magnification 100x. (c) Mean quantification of Runx1-positive cardiomyocyte nuclei (PCM-1+ and Runx1) expressed as a percentage of total nuclei (data from b). *P<0.05, 7 days after MI Ad-Runx1-shRNA vs. Ad-scramble-shRNA. (d) Echocardiography (scale: x=0.1 s; y=2 mm). (e) The 7-day echocardiographic data for fractional shortening (FS) of Ad-Runx1-shRNA (n=8; day 0, n=8; day 1, n=7; day 2, n=7; day 7) vs. Ad-scramble-shRNA (n=8; day 0, n=8; day 1, n=7; day 2, n=7; day 7). (f) Typical picrosirius-red-stained hearts and infarct size as the percentage of the left ventricle (n=3). (g) Schematic representation of AAV given via tail vein injection (h) Typical images of regional heart sections by RNA in situ hybridisation (using RNAscope). Regions examined were the RZ (AAV-Runx1-shRNA [n=3] vs. AAV-scramble-shRNA injected mice [n=3]), IZ (AAV-Runx1-shRNA [n=3] vs. AAV-scramble-shRNA injected mice [n=3]), and BZ (AAV-Runx1-shRNA [n=6] vs. AAV-scramble-shRNA injected mice [n=5]), at 7 days post-MI. Probes for Runx1
(pink punctate dots) and pericentriolar material 1 (PCM-1) (brown punctate dots) were used. Scale bar, 10 µm; magnification 100x. (i) Mean quantification of Runx1 positive cardiomyocyte nuclei (PCM-1+ and Runx1) expressed as a percentage of total nuclei (data from h). * = P<0.05, 7 days after MI AAV-Runx1-shRNA vs. AAV-scramble-shRNA. (j) Echocardiography (scale: x=0.1 s; y=2 mm). (k) The 7-day echocardiographic data for fractional shortening (FS) (AAV-Runx1-shRNA [n=9; day 0, n=9; day 1, n=9; day 7] vs. AAV-scramble-shRNA [n=10; day 0, n=10; day 1, n=9; day 7]). (l) Typical picrosirius-red stained hearts and infarct size as the percentage of the left ventricle AAV-Runx1-shRNA injected mice (n=8) vs. AAV-scramble-shRNA injected mice (n=6)). Error bars represent mean ± SEM. * P<0.05, Student t test.

Figure 5. Cardiac function and Runx1 expression in Ro5-3335 treated MI mice and CbfβΔ/Δ MI mice. (a) Protocol. (b) The 7-day echocardiographic data for fractional shortening (FS) for mice receiving protocol 1: Ro5-3335-treated MI mice (n=6; day 0, n=6; day 1, n=5; day 3, n=5; day 7) vs. vehicle (DMSO)-treated MI mice (n=6; day 0, n=5; day 1, n=3; day 3, n=4; day 7). (c) The 7-day echocardiographic data for FS for mice receiving protocol 2: Ro5-3335-treated mice (n=8; day 0, n=8; day 1, n=6; day 3, n=6; day 7) vs. vehicle (DMSO)-treated mice (n=7; day 0, n=8; day 1, n=3; day 3, n=7; day 7). *P<0.05, Student t test. (d) Runx1 mRNA expression relative to Peptidylprolyl Isomerase B (Ppib) as measured by real-time quantitative polymerase chain reaction (qPCR) in LV tissue from Ro5-3335-treated MI mice (n=6) vs. vehicle (DMSO)-treated MI mice (n=4). ***P<0.005, Student t test. (e) Protocol. (f) Runx1 mRNA expression relative to Ppib as measured by qPCR in LV tissue from CbfβΔ/Δ MI mice (n=4) vs. Cbfβfl/fl MI mice (n=4). (g) Runx1 mRNA expression relative to Ppib as measured by qPCR in LV isolated cardiomyocytes from CbfβΔ/Δ MI mice (n=9) vs. Cbfβfl/fl MI mice (n=8). *P<0.05, Student t test. (h) The 7-day echocardiographic data for FS for from CbfβΔ/Δ MI mice (n=8; day 0, n=6; day 1, n=6; day 7) vs. Cbfβfl/fl MI mice (n=6; day 0, n=5 day 1, n=6; day 7). Error bars represent mean ± SEM. *P<0.05, Student t test.
Figure 6. RNA sequencing comparisons and analysis between hearts 7 days post-myocardial infarction (MI) and pre-MI from Cbfβfl/fl and CbfβΔ/Δ mice.

(a) Schematic of comparison and Venn diagram of gene expression. (b) Volcano plots of differentially regulated genes unique to Cbfβfl/fl mice (left, black) and CbfβΔ/Δ mice (right, green) 7 days post-MI compared to pre-MI. Top five upregulated and down regulated genes based on false discovery rate (FDR) noted. (c) Enriched biological pathway from ingenuity pathway analysis (IPA) analysis generated from unique differences in Runx1fl/fl (border zone, BZ vs remote zone, RZ) and Cbfβfl/fl (post-MI vs Pre-MI) mice ranked on Z-score. Blue to orange heatmap and symbol colours represent predicted inhibition (blue) and activation (orange) or no change (white) of pathways based on Z-score. Schematic representation of genes involved in oxidative phosphorylation complexes from RNAseq IPA pathway analysis generated from all gene differences (downregulated – green, upregulated – red, no difference – white) between day 7 post-MI and pre-MI in (d) Cbfβfl/fl (7860 differentially expressed genes) and (e) CbfβΔ/Δ mice (2995 differentially expressed genes).
**Figure 1**

**a** C57BL6 or Runx1Δ/Δ

Cardiomyocyte isolation

- Remote zone (RZ)
- Border zone (BZ)

Pre-MI or Day 1 Post-MI

**b**

Pre-MI C57BL6

- “RZ” (black line)
- “BZ” (gray line)

**c**

Caffeine-induced Ca\(^{2+}\) transient peak (% of RZ)

**d**

Caffeine-induced Ca\(^{2+}\) transient amplitude (% of RZ)

**e**

Caffeine-induced Ca\(^{2+}\) transient amplitude (% of RZ)

**f**

K\(_{SERCA}\) (% of RZ)

**g**

Day 1 Post-MI C57BL6

- RZ (black line)
- BZ (gray line)

**h**

Caffeine-induced Ca\(^{2+}\) transient peak (% of RZ)

**i**

Caffeine-induced Ca\(^{2+}\) transient amplitude (% of RZ)

**j**

Caffeine-induced Ca\(^{2+}\) transient amplitude (% of RZ)

**k**

K\(_{SERCA}\) (% of RZ)

**l**

Day 1 Post-MI Runx1Δ/Δ

- RZ (black line)
- BZ (gray line)

**m**

Caffeine-induced Ca\(^{2+}\) transient peak (% of RZ)

**n**

Caffeine-induced Ca\(^{2+}\) transient amplitude (% of RZ)

**o**

Caffeine-induced Ca\(^{2+}\) transient amplitude (% of RZ)

**p**

K\(_{SERCA}\) (% of RZ)
Differences in Day 1 Post-MI Runx1\(^{Δ/Δ}\) vs. Runx1\(^{fl/fl}\) Runx1\(^{fl/fl}\) vs. Runx1\(^{Δ/Δ}\) Both RNAseq comparison: Border zone (BZ) vs. Remote zone (RZ)

Log2 Fold Change -8 -4 -6 -2 0 2 4 8 6

-Log10 False Discovery Rate 0 20 40 60 80

Figure 2

Enriched Pathways and Functions (5548 and 130)

Oxidative Phosphorylation
Valine Degradation
Fat Acid - Oxidation
HER-2 Signalling in Breast Cancer
PI3K/AKT Signalling
Eif2 Signalling
Integrin Signalling
NAD Signalling Pathway
Actin Cytoskeleton Signalling
RAC Signalling
Xenobiotic Metabolism Signalling Pathway
14-3-3-mediated Signalling
Acute Phae Response Signalling
Chemokin Signalling
Kinetochore Metaphase Signalling Pathway
Valine Degradation I
Fatty Acid - Oxidation I
Acute Phae Response Signalling
Chemokin Signalling
Kinetochore Metaphase Signalling Pathway
Valine Degradation I
Fatty Acid - Oxidation I
Figure 3
Differences in Border Zone vs. Remote Zone: Oxidative Phosphorylation

Runx1fl/fl vs. Runx1Δ/Δ
- No difference
- Downregulated
- Upregulated

Runx1fl/fl
- Mitophagosome
- Damaged cristae

Runx1Δ/Δ
- Mitochondrial matrix
- Complex V

Mito density (% of cell area)

Average mitochondrion size (µm²)
C57BL6 with MI

Ro5-3335 (20mg/kg) or Vehicle

Protocol 1:

Protocol 2:

Figure 5

Protocol 1

Fractional Shortening (%)

0 1 2 3 4 5 6 7

Days post-MI

Protocol 2

Fractional Shortening (%)

0 1 2 3 4 5 6 7

Days post-MI

LV Runx1 expression (2^{-\Delta CT})

0 0.2 0.4 0.6 0.8

Days post-MI

CBFβ expression

cardiomyocytes (2^{-\Delta CT})

0 0.2 0.4 0.6 0.8

Days post-MI

CBFβ expression

tissue (2^{-\Delta CT})

0 0.2 0.4 0.6 0.8

Days post-MI

CBFβ expression

Post-MI Post-MI

CBFβ^{fl/fl} x MerCreMer alpha-myosin heavy chain

CBFβ^{fl/fl} CBFβ^{A/A}
**Figure 6**

**a**

RNAseq comparison: Day 7 Post-MI vs. Pre-MI

Differences in Day 7 Post-MI vs. Pre-MI

- CBFβ\(^{fl/fl}\) (7860)
- CBFβ\(^{Δ/Δ}\) (2995)
- Both (2747)
- CBFβ\(^{Δ/Δ}\) vs. Pre-MI (248)

**b**

- Log2 Fold Change
- -Log10 False Discovery Rate
- -Log10 False Discovery Rate

- Log2 Fold Change
- -Log10 False Discovery Rate
- -Log10 False Discovery Rate

**c**

- Oxidative Phosphorylation
- Phagosome Formation
- Neuroinflammation Signalling
- Role of Hypercytokinemia
- Hepatic Fibrosis Signalling
- Ephrin Receptor Signalling
- RAC Signalling
- FcγR-mediated Phagocytosis
- TREM1 Signalling
- HER-2 Signalling
- GP6 Signalling Pathway
- Tumour Microenvironment
- PPAR Signalling
- IL-8 Signalling
- Actin Cytoskeleton Signalling
- EIF2 Signalling
- Integrin Signalling
- TCA Cycle II (Eukaryotic)
- Kinetochoore Metaphase
- MSP-RON Signalling
- Production of Nitric Oxide
- PI3K/AKT Signalling
- Pulmonary Fibrosis
- ERK/MAPK Signalling

**d**

Differences in Day 7 Post-MI vs. Pre-MI: Oxidative Phosphorylation

**e**

- CBFβ\(^{fl/fl}\)
- CBFβ\(^{Δ/Δ}\)
- No difference
- Downregulated
- Upregulated

Legend:

- Complex
- Chemical/Toxicant
- Enzyme
- Graphic node
- Group/Complex
- Transporter
- Other
- Relationship
- Relationship

The copyright holder for this version posted February 19, 2022. doi: bioRxiv preprint